Extended interval bisphosphonate dosing: A focus on zoledronic acid (Reclast®)
Metadata[+] Show full item record
The once-yearly intravenous bisphosphonate, zoledronic acid (Reclast®), is an effective therapy for the treatment of postmenopausal osteoporosis and secondary prevention of fractures in patients with adequate calcium and vitamin D supplementation. Long-term safety is unknown. One phase III trial showed a decreased mortality rate, whereas another showed an increase in atrial fibrillation.
Evidence Based Practice 12(9): 14-15.